The firm is adding to its Biotechnology research coverage with a focus on targeted protein degradation, or TPD, technology and commercial and clinical-stage rare disease-focused companies. Arvinas ...
Stephens analyst Sudan Loganathan initiated coverage of Kymera Therapeutics (KYMR) with an Overweight rating and $65 price target The firm is adding to its Biotechnology research coverage with a focus ...
Results that may be inaccessible to you are currently showing.